The company Mazor Robotics won FDA approval to apply its robotic surgical system to neurosurgery in July 2012. In the same month, the flagship company Corindus won FDA approval for its CorPath 200 System to be used in performing percutaneous coronary interventions (PCI). The technology is now approved in the United States to assist interventional cardiologists in performing PCI, a procedure to restore blood flow to blocked arteries in patients with coronary artery disease (CAD).Recent global headlines have evidenced the ongoing miracle of Israel’s ability to translate new discoveries into patented innovations that become applicable on world markets. In the past two months, two flagship companies created through the dynamic activities of the T3 – the Technion office of Technology Transfer, passed the key milestone and significant hurdle in the process of effective technology transfer, with the reception of approval from the US Food and Drug Administration (FDA).
The mission of T3 – the technology transfer arm of the Technion, is to transform scientiﬁc discoveries and innovative technologies into real-life, applied solutions for the advancement of humanity, the State of Israel, and the Technion. By creating optimal alliances between scientists, industry and investors, T3 facilitates the smooth transfer of technologies to the commercial sector. This is accomplished through the licensing of intellectual property and the establishment of start-up companies. Occasionally, T3 also plays an active role as an entrepreneur by building teams, preparing business plans and providing the capital necessary to bring the technologies developed by Technion researchers to maturity.
The Technion – Israel Institute of Technology is Israel’s ﬁrst university and home to three Nobel Laureates. The Technion is credited worldwide for its ability to generate start-ups, its remarkable ability to innovate and its powerful connections to industry. Known as “Israel’s MIT,” the Technion has made a signiﬁcant impact across the range of applied science and technology including electronics, information technology, water management, nanotechnology, life sciences & chemistry, clean-tech, materials engineering and aerospace engineering.
During the past years, T3 has enjoyed a robust and marked increase both in the number of patent families originating from Technion research as well as in the number of commercialization successes. With 80-100 new patent ﬁlings every year, over 400 granted patents and over 900 pending patents, Technion now has approximately 400 patent families available for commercialization.